A new validation study on the prognostic performance of Stratipath Breast.
Stratipath is excited to announce the publication of a new validation study on the prognostic performance of Stratipath Breast—the first AI-based CE-marked medical device for risk stratification of breast cancer using routine H&E histopathology images.
